NEW YORK, NY / ACCESS Newswire / March 4, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Viatris Inc. ("Viatris Inc.") (NASDAQ:VTRS) concerning possible ...

Nxera Pharma has sold the Asia-Pacific rights to Idorsia's phase 3-stage autoimmune drug to Viatris for $10 million upfront. The drug in question is cenerimod, a S1P1 receptor modulator currently ...

Barclays analyst Balaji Prasad lowered the firm’s price target on Viatris (VTRS) to $9 from $12 and keeps an Underweight rating on the shares. The stock fell 15% on the Indore Facility impacting ...

Viatris Inc (Symbol: VTRS) presently has an above average rank, in the top 50% of the coverage universe, which suggests it is among the top most "interesting" ideas that merit further research by ...

Shares of medication company Viatris (NASDAQ:VTRS) fell 16.9% in the morning session after the company reported disappointing fourth-quarter 2024 results, with sales, earnings, and operating ...

Shares of Viatris (NASDAQ:VTRS) slipped ~12% in the premarket on Thursday after the generic drugmaker, with its Q4 2024 results, set its full-year outlook below expectations amid a negative impact ...

PITTSBURGH, Feb. 27, 2025 /PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS) today announced that on February 24, 2025, its Board of Directors approved a 2025 dividend policy of 48 cents ($0.48 ...

Free cash flow rose to $685 million, marking a 26.1% increase year-over-year. Viatris reported mixed results for Q4 2024, missing revenue and EPS expectations, despite noteworthy debt reduction ...

Viatris Inc (NASDAQ:VTRS) reported its fourth-quarter earnings for 2024, revealing a mixed financial performance. The company posted an earnings per share (EPS) of $0.54, falling short of the $0. ...

Such forward looking statements may include statements regarding Viatris' 2025 dividend policy of 48 cents ($0.48) per share and Viatris declaring a quarterly dividend of 12 cents ($0.12 ...

Viatris is one of the largest generic drug manufacturers in the world. Generic drugs make up about 40% of the firm's sales and, along with other generics manufacturers, they continues to suffer ...